De Schepper P - Search Results

1

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.

Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, De Schepper P, Mehlisch DR, Gertz BJ. Ehrich EW, et al. Among authors: de schepper p. Clin Pharmacol Ther. 1999 Mar;65(3):336-47. doi: 10.1016/S0009-9236(99)70113-X. Clin Pharmacol Ther. 1999. PMID: 10096266 Clinical Trial.

2

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

Dallob A, Hawkey CJ, Greenberg H, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K. Dallob A, et al. Among authors: de schepper p. J Clin Pharmacol. 2003 Jun;43(6):573-85. J Clin Pharmacol. 2003. PMID: 12817520 Clinical Trial.

3

Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans.

Depre M, Friedman B, Tanaka W, Van Hecken A, Buntinx A, DeSchepper PJ. Depre M, et al. Clin Pharmacol Ther. 1993 May;53(5):602-7. doi: 10.1038/clpt.1993.76. Clin Pharmacol Ther. 1993. PMID: 8387904 Clinical Trial.

4

Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans.

Depré M, Ehrich E, Van Hecken A, De Lepeleire I, Dallob A, Wong P, Porras A, Gertz BJ, De Schepper PJ. Depré M, et al. Among authors: de schepper pj. Eur J Clin Pharmacol. 2000 May;56(2):167-74. doi: 10.1007/s002280050736. Eur J Clin Pharmacol. 2000. PMID: 10877012 Clinical Trial.

5

Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.

Van Hecken A, Schwartz JI, Depré M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ. Van Hecken A, et al. Among authors: de schepper pj. J Clin Pharmacol. 2000 Oct;40(10):1109-20. J Clin Pharmacol. 2000. PMID: 11028250 Clinical Trial.

6

Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration.

Dallob A, De Lepeleire I, Van Hecken A, Porras A, Depré M, Mukhopadhyay S, Flynn M, Wildonger L, Gottesdiener K, Tanaka W, De Schepper P. Dallob A, et al. Among authors: de schepper p. Inflamm Res. 1999 Dec;48 Suppl 2:S130-1. doi: 10.1007/s000110050552. Inflamm Res. 1999. PMID: 10667849 Clinical Trial. No abstract available.

7

Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor.

Depré M, Friedman B, Van Hecken A, de Lepeleire I, Tanaka W, Dallob A, Shingo S, Porras A, Lin C, de Schepper PJ. Depré M, et al. Among authors: de lepeleire i, de schepper pj. Clin Pharmacol Ther. 1994 Jul;56(1):22-30. doi: 10.1038/clpt.1994.96. Clin Pharmacol Ther. 1994. PMID: 8033491 Clinical Trial.

8

Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.

Schwartz JI, Van Hecken A, De Schepper PJ, De Lepeleire I, Lasseter KC, Shamblen EC, Winchell GA, Constanzer ML, Chavez CM, Wang DZ, Ebel DL, Justice SJ, Gertz BJ. Schwartz JI, et al. Among authors: de lepeleire i, de schepper pj. J Clin Endocrinol Metab. 1996 Aug;81(8):2942-7. doi: 10.1210/jcem.81.8.8768856. J Clin Endocrinol Metab. 1996. PMID: 8768856 Clinical Trial.

9

Pharmacokinetic and pharmacodynamic interaction between the lipoxygenase inhibitor MK-0591 and the cyclooxygenase inhibitor ibuprofen in man.

Depré M, Van Hecken A, Verbesselt R, De Lepeleire I, Schwartz J, Porras A, Larson P, Lin C, De Schepper PJ. Depré M, et al. Among authors: de schepper pj. Int J Clin Pharmacol Res. 1998;18(2):53-61. Int J Clin Pharmacol Res. 1998. PMID: 9675622 Clinical Trial.

10

Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Van Hecken A, Depré M, Verbesselt R, Wynants K, De Lepeleire I, Arnout J, Wong PH, Freeman A, Holland S, Gertz B, De Schepper PJ. Van Hecken A, et al. Among authors: de schepper pj. J Clin Pharmacol. 1999 May;39(5):495-500. J Clin Pharmacol. 1999. PMID: 10234597 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

100 results

Search Page